Effectiveness of lamotrigine in bipolar disorder in a clinical setting

Journal of Psychiatric Research
Terence KetterJulie C Bonner

Abstract

To assess lamotrigine effectiveness in bipolar disorder (BD) patients in a clinical setting. Open lamotrigine was naturalistically administered to outpatients at the Stanford University BD Clinic assessed with the Systematic Treatment Enhancement Program for BD (STEP-BD) Affective Disorders Evaluation, and monitored longitudinally with the STEP-BD Clinical Monitoring Form. One hundred and ninety-seven patients (64 BD I, 110 BD II, 21 BD NOS, 2 Schizoaffective Bipolar Type, mean+/-SD age 42.2+/-14.4 years, 62% female) had 200 trials of lamotrigine. Lamotrigine was combined with a mean of 2.1+/-1.5 other psychotropic medications, most often during euthymia or depressive symptoms. Mean lamotrigine duration was 434+/-444 days, and mean final dose was 236+/-132mg/day without valproate, and 169+/-137mg/day with valproate. Lamotrigine was discontinued in only 26.5% of trials at 255+/-242 days, most often due to inefficacy, and seldom due to adverse effects. In 31.5% of trials lamotrigine was continued 264+/-375 days with no subsequent psychotropic added. In 42.0% of trials lamotrigine was continued 674+/-479 days, but had subsequent psychotropic added at 146+/-150 days, most often for anxiety/insomnia and depressive symptoms. In 145 t...Continue Reading

References

Nov 21, 1990·JAMA : the Journal of the American Medical Association·D A RegierF K Goodwin
Dec 6, 2000·Journal of Clinical Psychopharmacology·M A FryeR M Post
Mar 5, 2002·The Journal of Clinical Psychiatry·David J KupferDebra A Stapf
Mar 5, 2002·The Journal of Clinical Psychiatry·Terence A Ketter, Joseph R Calabrese
Apr 3, 2002·The Journal of Clinical Psychiatry·Susan L McElroyRobert M Post
Jun 5, 2002·Archives of General Psychiatry·Lewis L JuddMartin B Keller
Nov 26, 2002·The Journal of Clinical Psychiatry·Joseph R CalabreseVivek Kusumakar
Feb 4, 2003·The British Journal of Psychiatry : the Journal of Mental Science·Laksami N YathamArun Ravindran
Apr 2, 2003·The American Journal of Psychiatry·Paul E KeckUNKNOWN Ziprasidone in Mania Study Group
Aug 29, 2003·The American Journal of Psychiatry·Paul E KeckUNKNOWN Aripiprazole Study Group
Nov 12, 2003·Archives of General Psychiatry·Mauricio TohenAlan Breier
Nov 25, 2003·The Journal of Clinical Psychiatry·Joseph R CalabreseUNKNOWN Lamictal 605 Study Group
Apr 21, 2004·The Journal of Clinical Psychiatry·Guy M GoodwinRobert Leadbetter
Jun 1, 2004·The American Journal of Psychiatry·Robert M A HirschfeldFred Grossman
Nov 13, 2004·Journal of Clinical Psychopharmacology·Lakshmi N YathamAnd Mårten Vågerö
Dec 2, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Anatoly B SmulevichFred Grossman
May 3, 2005·The American Journal of Psychiatry·John S MarchRanga Krishnan
May 14, 2005·The Journal of Clinical Psychiatry·Terence A KetterMatthew R Schumacher
Jul 14, 2005·Journal of Clinical Psychopharmacology·Steven G PotkinPatricia English
Sep 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Sumant KhannaMichelle Kramer
Sep 6, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Roger S McIntyreJamie Mullen
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Oct 22, 2005·Biological Psychiatry·Joseph Biederman, Regina Smith James
Mar 7, 2006·Journal of Psychiatric Research·Po W WangTerence A Ketter
May 4, 2006·The Journal of Clinical Psychiatry·Paul E KeckUNKNOWN Aripiprazole Study Group
Jul 4, 2006·The American Journal of Psychiatry·Charles L BowdenThomas R Thompson
Jan 30, 2007·Current Medical Research and Opinion·Terence A Ketter, Dan W Haupt
Mar 30, 2007·The New England Journal of Medicine·Gary S SachsMichael E Thase

❮ Previous
Next ❯

Citations

Oct 29, 2011·European Archives of Psychiatry and Clinical Neuroscience·Thomas C BaghaiUNKNOWN Section of Pharmacopsychiatry, World Psychiatric Association
Feb 5, 2009·International Clinical Psychopharmacology·Soo Hyun JoeKyooseob Ha
Aug 3, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Jae Seung ChangKyooseob Ha
Jan 14, 2012·Journal of Affective Disorders·Pichai IttasakulTerence A Ketter
Apr 6, 2018·Journal of Clinical Psychopharmacology·Shefali MillerTerence A Ketter
Nov 12, 2015·Frontiers in Pharmacology·Kedar S PrabhavalkarLokesh K Bhatt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.